Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Healthy Living Europe.
Press releases published on July 15, 2025
ZEVASKYN™ Gene Therapy Now Available at New Qualified Treatment Center in San Francisco Bay Area
GlobeNewswire
·
July 15, 2025
- Lucile Packard Children’s Hospital Stanford is ready to accept patients for ZEVASKYN treatment - - Abeona Therapeutics® and Stanford Medicine conducted research collaboration for more than a decade, culminating in U.S. Food and Drug Administration (FDA) …
BriaCell Adds Mayo Clinic to Phase 3 Study in Metastatic Breast Cancer
GlobeNewswire
·
July 15, 2025
PHILADELPHIA and VANCOUVER, British Columbia, July 15, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to …
ProKidney Announces Alignment with the FDA on the Accelerated Approval Pathway for Rilparencel
GlobeNewswire
·
July 15, 2025
FDA confirmed that eGFR slope is an acceptable surrogate endpoint for accelerated approval of rilparencel in patients with CKD and type 2 diabetes FDA also confirmed that the ongoing Phase 3 PROACT 1 study can be used for both accelerated approval and for …
Neuronetics Appoints New Chief Financial Officer
GlobeNewswire
·
July 15, 2025
Steven Pfanstiel, a seasoned financial executive with extensive medical technology and pharmaceutical experience, replaces Steve Furlong as Chief Financial Officer following previously announced succession process Neuronetics reiterates guidance for second …
Plus Therapeutics Presents ReSPECT-LM Clinical Trial Results for REYOBIQ™ in Patients with Leptomeningeal Metastases
GlobeNewswire
·
July 15, 2025
Presentation by trial principal investigator at the 2025 SNO/ASCO CNS Metastases Conference Plus will also host an educational symposium with leading experts titled, “Reimagining Your Approach to Leptomeningeal Metastases” HOUSTON, July 15, 2025 (GLOBE …
Aurora Spine Announces Participation in 7th Annual American Society of Pain & Neuroscience Conference
GlobeNewswire
·
July 15, 2025
CARLSBAD, California, July 15, 2025 (GLOBE NEWSWIRE) -- Aurora Spine Corporation (“Aurora Spine” or the “Company”) (TSXV: ASG) (OTCQB: ASAPF), a leader in innovative spine and interventional pain management solutions, today announced it will be …
60 Degrees Pharmaceuticals Defines Potential Human Babesiosis Market Size for ARAKODA® (tafenoquine): Annual Max TAM, Sales of $245 Million; Cumulative through Patent Expiration, $1.1 Billion
GlobeNewswire
·
July 15, 2025
New Drug Application intended for 2026, subject to generation of positive data from three U.S. clinical trials planned or in progress Total addressable market (TAM) for ARAKODA for Human Babesiosis is informed by results of a 6,000 nationwide patient …
Addgene Announces Strategic Partnership with Promega to Launch Plasmid Collection
GlobeNewswire
·
July 15, 2025
WATERTOWN, Mass., July 15, 2025 (GLOBE NEWSWIRE) -- Addgene, a purpose-driven organization helping scientists conduct experiments with greater ease, speed, and reproducibility, today announced a strategic partnership with Promega to expand Addgene’s vast …
AAFA Names Matthew Greenhawt Chief Medical Officer
GlobeNewswire
·
July 15, 2025
Washington, DC, July 15, 2025 (GLOBE NEWSWIRE) -- The Asthma and Allergy Foundation of America (AAFA) today announced that Matthew Greenhawt, MD, MBA, MSc, has joined the organization as Chief Medical Officer. In this new role, Dr. Greenhawt will help …
Acumen Pharmaceuticals and JCR Pharmaceuticals Enter Strategic Collaboration, Option and License Agreement to Develop Enhanced Brain Delivery™ Therapy for Alzheimer’s Disease
GlobeNewswire
·
July 15, 2025
Acumen and JCR aim to develop a product leveraging Acumen’s amyloid beta oligomer-selective antibody expertise and JCR’s transferrin-receptor-targeting blood-brain barrier-penetrating technology Preclinical candidate data expected in early 2026, with …
Adagene Announces Regulatory Update on Clinical Development Plan for Muzastotug in Microsatellite Stable Colorectal Cancer Following Productive Type B (End of Phase 1) Meeting with FDA
GlobeNewswire
·
July 15, 2025
- Alignment gained on Phase 2 inclusion/exclusion criteria, primary and secondary endpoints, and study design, including sample size and dosing regimen - Company expects to begin enrolling patients in Phase 2 in 2H 2025 SAN DIEGO and SUZHOU, China, July 15 …
AAVantgarde Receives FDA Clearance to Progress Stargardt Disease Asset, AAVB-039, into CELESTE, a Phase 1/2 Clinical Trial
GlobeNewswire
·
July 15, 2025
AAVB-039 delivers the full-length ABCA4 -protein, addressing the root cause of the disease and enabling treatment of all patients, independent of mutation CELESTE is informed by the STELLA prospective natural history study, which is currently enrolling …
Apellis Announces Five Abstracts Accepted for Oral Presentation at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting
GlobeNewswire
·
July 15, 2025
WALTHAM, Mass., July 15, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that five abstracts were accepted for oral presentation at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting to be held …
Verano Announces Promotion and Appointment of James Leventis as Chief Strategy and Compliance Officer
GlobeNewswire
·
July 15, 2025
CHICAGO, July 15, 2025 (GLOBE NEWSWIRE) -- Verano Holdings Corp. (Cboe CA: VRNO) (OTCQX: VRNOF) (“Verano” or the “Company”), a leading multi-state cannabis company, today announced the promotion and appointment of James Leventis as the Company’s Chief …
Aquestive Therapeutics Provides International Expansion Update for Anaphylm™ (epinephrine) Sublingual Film
GlobeNewswire
·
July 15, 2025
New Drug Submission meeting scheduled with Health Canada for the third quarter of 2025 Initial briefing book submitted for review to the European Medicines Agency WARREN, N.J., July 15, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) …
Merakris Therapeutics Selected as Finalist for 2025 Advanced Would Care Summit Innovation Showcase
GlobeNewswire
·
July 15, 2025
RESEARCH TRIANGLE PARK, N.C., July 15, 2025 (GLOBE NEWSWIRE) -- Merakris Therapeutics announces its amniotic fluid-derived regenerative biologic, MTX-001, an investigational new drug, is a finalist for the Innovation Showcase: Early-Stage Disruptors in …
Teladoc Health Launches Wellbound Employee Assistance Program (EAP)
GlobeNewswire
·
July 15, 2025
NEW YORK, July 15, 2025 (GLOBE NEWSWIRE) -- Teladoc Health (NYSE: TDOC), the global leader in virtual care, today announced the launch of Wellbound, a bold new employee assistance program (EAP) designed to empower a more engaged, healthier workforce. The …
Award-Winning Actress and Advocate Terri J. Vaughn to Headline Inaugural Pennsylvania Maternal Health Summit
GlobeNewswire
·
July 15, 2025
Lancaster, Pennsylvania, July 15, 2025 (GLOBE NEWSWIRE) -- Acclaimed actress, producer, and maternal health advocate Terri J. Vaughn will serve as the keynote speaker for the first-ever Pennsylvania Maternal Health Summit, taking place Wednesday, August 6, …
4TEEN4 Announces Publication in European Journal of Heart Failure Demonstrating First-in-Human Shock Reversal Evidence for Procizumab in Three Compassionate Use Cases
GlobeNewswire
·
July 15, 2025
Data from three terminally ill cardiogenic shock patients showcase potential of procizumab to safely reverse shock within 48 hours and provide promising first-in-human evidence on the translatability of preclinical efficacy to humans Procizumab is a first- …
Draig Therapeutics Appoints Experienced Biotech Leader Douglas E. Williams, Ph.D. as Chair of its Board of Directors
GlobeNewswire
·
July 15, 2025
Strong track record at executive and board level of building company value across all stages of development including supporting the development of multiple blockbuster medicines Cardiff, United Kingdom – 15 July 2025 – Draig Therapeutics (“Draig”), a …